...
首页> 外文期刊>Journal of Clinical Microbiology >When To Retest: an Examination of Repeat COVID-19 PCR Patterns in an Ambulatory Population
【24h】

When To Retest: an Examination of Repeat COVID-19 PCR Patterns in an Ambulatory Population

机译:何时重新测试:对动态人群的重复Covid-19 PCR模式进行检查

获取原文
           

摘要

LETTER Health care facilities have limited supplies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) amplification/detection, putting them under pressure to optimize reagent use. Repeat testing is a potential source of waste. CDC guidelines list screening criteria but only specify return-to-work criteria for health care providers (HCP), which divides the criteria into symptom-based, time-based, and testing based strategies ( 1 ). The testing-based strategy suggests two negative tests at least 24?h apart for clearance. However, these guidelines are for people who have initially tested positive. The Infectious Diseases Society of America (IDSA) recently recommended repeat testing in symptomatic individuals with a sustained clinical suspicion of COVID-19 when the initial test is negative; however, the panel noted the paucity of clinical evidence regarding repeat testing ( 2 ). The purpose of this quality improvement study was to see if we could better understand the clinical utility of repeat SARS-CoV-2 PCR testing. Washington Kaiser Permanente (KPWA) is an integrated health care network with a central laboratory performing testing exclusively for outpatient/ambulatory members following the WHO screening criteria. All SARS-CoV-2 molecular testing has been performed as a send-out to the University of Washington (UW), which uses a combination of the Roche Cobas, Hologic Panther Fusion, and their laboratory-developed test (LDT) ( 3 ), or internally at the KPWA central laboratory, which utilizes the Hologic Panther Fusion. SARS-CoV-2 PCR results between 6 March 2020 and 30 April 2020 were extracted and reviewed. From 6 March 2020 to 20 April 2020, these were exclusively nasopharyngeal swabs ( n ?=?6,411); after 20 April 2020, nasal swabs were validated as an additional source. In total, 8,391 tests were performed on 8,084 unique patients ( n ?=?4,112 Fusion, n ?=?3,492 UW LDT, and n ?=?787 Cobas; median age, 49?years [interquartile range, 34 to 62]). Of these, 7.1% of testing ( n ?=?597 tests) was performed on patients who had more than one SARS-CoV-2 PCR test ( n ?=?290 unique patients), with the majority (95.2%) having received 2 tests and the minority having received 3 ( n ?=?11; 3.8%) or 4 ( n = 3; 1.0%) tests. Most testing was ordered by family practice ( n ?=?4,829 tests; 57.5%), followed by urgent care ( n ?=?1,864; 22.2%), internal medicine ( n ?=?883; 10.5%), pediatrics ( n ?=?175; 2.1%), and other ( n ?=?640; 7.6%). The difference in the distribution of initial tests and repeat tests across departments was not statistically significant (χ ~(2) _(5) ?=?10.8; P ?=?0.056). For patients who had two tests (276 unique patients), 87.0% of the second tests (240 of 276) were concordant with the first test result ( Fig. 1 ). Of the discordant, 10 unique patients had a negative result on first swab and a positive result on second swab; of the concordant, 225 unique patients had negative results on first and second swabs; for patients with 3 tests with a negative result on the first swab ( n ?=?7), 100% were concordant negative. Only one patient received 4 tests with a negative on the first swab, the second of which was positive, and the following two were negative. The probability that the second test would be positive given that the first test was negative was 4.2% (95% confidence interval [CI], 2.0 to 7.6%). Logistic regression was used to evaluate the impact of time on the probability of a positive second test. Given an initial negative result, the probability of a positive result on a second test increased with the length of time between the initial and subsequent test (odds ratio?=?1.04; 95% CI, 1.00 to 1.09; P ?=?0.03). Chart review indicated that 55% of the patients with positive second tests were HCP or had experienced additional exposures, prolonged symptoms, or symptoms that recurred after a resolution period. Thus, repeat testing after a negative result is more likely to be useful when there is strong clinical suspicion of COVID. FIG 1 Violin plot illustrating comparison of results between consecutive testing for people with two SARS-CoV-2 PCR tests ( n ?=?276). Sample size indicates the number of unique patients who had two tests within each cohort. Hollow circle indicates median. Note that patients with 3 or more tests were excluded from this figure. Recommendations discourage a testing-based strategy for cure since symptom/time-based strategies are better indicators of resolution ( 4 ). In this data set, 37 unique patients ( n = 78 tests) had at least one follow-up test after a positive result. For these, the mean testing interval was 19.3?days (interquartile range, 10 to 25?days), and 32.4% of the pairs ( n ?=?12 patients) were performed on HCP or people with similar high-risk employment; 16.2% ( n ?=?6 patients) were performed for preprocedure clearance. Patients whose repeat test was positive were likely retested too soon after initial test result ( Fig. 1 ). Indeterminate results
机译:信件保健设施为严重急性呼吸综合征冠状病毒2(SARS-COV-2)扩增/检测有限,使其在压力下进行优化试剂使用。重复测试是潜在的浪费来源。 CDC指南列出了筛选标准,但仅指定医疗保健提供者(HCP)的返回工作标准,该标准将该标准划分为基于症状,时间的时间和基于时间的策略(1)。基于测试的策略表明,除了间隙至少24的两个负面测试。但是,这些准则是初始测试积极的人。美国的传染病学会(IDSA)最近在初始试验较为负时持续临床怀疑的临床疾病的持续临床怀疑;但是,小组注意到关于重复测试的临床证据(2)的缺乏。这种质量改进研究的目的是看看我们是否可以更好地理解重复SARS-COV-2 PCR测试的临床效用。华盛顿Kaiser Permanente(KPWA)是一家集成的医疗保健网络,具有中央实验室,专门用于关注WHO筛选标准的门诊/动态成员。所有SARS-COV-2分子测试都是作为华盛顿大学(UW)的发货,它使用罗氏COBAS,HOLOGIC PANTHER FUSENT及其实验室开发的测试(LDT)(3)的组合,或内部在KPWA中央实验室,利用HOLOGIC PANTHER FUSTION。 SARS-COV-2 PCR结果在2020年3月6日至4月30日之间提取并审查。从2020年3月6日至4月20日,这些是鼻咽拭子(N?=?6,411); 2020年4月20日之后,鼻拭子被验证为额外的来源。总共对8,084名独特的患者进行了8,391次测试(n?= 4,112融合,n?= 3,492 uw ldt,和n?=?787个圆盘;中位年龄,49?年[四分位数,34到62]) 。其中,7.1%的测试(n?= 597测试)是对具有多个SARS-COV-2 PCR测试的患者进行(N?= 290个独特的患者),其中大多数(95.2%)收到2测试和接收的少数群体3(n?=?11; 3.8%)或4(n = 3; 1.0%)测试。大多数测试由家庭练习(n?= 4,829次测试; 57.5%),其次是紧急护理(n?= 1,864; 22.2%),内科(n?= 883; 10.5%),儿科(n ?=?175; 2.1%),其他(n?=?640; 7.6%)。初始试验分布和跨部门的重复测试的差异在统计学上没有统计学意义(χ〜(2)_(5)?=?10.8; p?= 0.056)。对于有两次测试(276名独特患者)的患者,87.0%的第二次测试(276个中的276个)与第一个测试结果相应(图1)。不和谐,10名独特的患者在第一次拭子上的负面结果和第二次拭子上的阳性结果;在一致的一声协调中,225名独特的患者在第一款和第二次拭子上有负面结果;对于第一个拭子上的阴性结果3次测试的患者(n?= 7),100%是负面的阴性。只有一个患者在第一个拭子上接受了4个患者,其中第二个是阳性的,第二个是阳性的,并且以下两个是阴性的。鉴于第一次试验为阴性的第二种测试的常数是阳性的概率为4.2%(95%置信区间[CI],2.0至7.6%)。 Logistic回归用于评估时间对正秒第二测试概率的影响。鉴于初始阴性结果,第二次测试的阳性结果的概率随着初始和后续测试之间的时间长度而增加(差距α=Δ1.04; 95%CI,1.00至1.09; P?= 0.03) 。图表审查表明,55%的患有阳性第二次测试的患者是HCP,或者在解决期间经历了额外的曝光,长期症状或症状。因此,在阴性效果后重复测试在临床怀疑的临床怀疑时更可能是有用的。图1小提琴图,说明了与两个SARS-COV-2 PCR测试的人们连续测试之间的结果进行比较(n?= 276)。样本大小表示每个群组中有两次测试的独特患者的数量。空心圆圈表示中位数。请注意,患有3个或更多次测试的患者被排除在此图中。建议阻止基于测试的治疗策略,因为症状/时间的策略是决议的更好指标(4)。在此数据集中,37名独特的患者(n = 78次测试)在阳性结果后至少进行一次后续测试。为此,平均测试间隔为19.3?天(四分位数,10至25个?天),以及对HCP或具有相似高风险工作的人进行对(n?= 12名患者)的32.4%;进行16.2%(N?= 6例患者)进行预造型间隙。在初始测试结果之后,重复测试阳性的患者可能会重新测试(图1)。不确定的结果

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号